Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
07:00am, Wednesday, 11'th Dec 2024
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
01:05pm, Friday, 29'th Nov 2024
PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript
02:06pm, Wednesday, 13'th Nov 2024
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Exe
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
07:00am, Thursday, 07'th Nov 2024
PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
08:00am, Wednesday, 30'th Oct 2024
PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an
SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade
Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq
PolyPid to Participate in Three Upcoming Fall Investor Conferences
07:00am, Tuesday, 03'rd Sep 2024
PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today
PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript
01:25pm, Wednesday, 14'th Aug 2024
PolyPid Ltd (NASDAQ:PYPD ) Q2 2024 Results Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chie
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
08:31pm, Thursday, 01'st Aug 2024
Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
07:00am, Wednesday, 31'st Jul 2024
PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial
07:00am, Monday, 10'th Jun 2024
PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript
10:38pm, Thursday, 09'th May 2024
PolyPid Ltd (NASDAQ:PYPD ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - IR Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 08'th May 2024
More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
